DEUTERIERTES MOMELOTINIB

European patent · EP2943489 · In force

Register entry

Publication number
EP2943489
Application number
EP14738035
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jan 8, 2014
Published
Nov 18, 2015
Granted
Apr 11, 2018
Protection ends at the latest
Jan 7, 2034
Next annual fee due
Jan 31, 2027
IPC classes
C07D 239/42 (2006.01)
A61K 31/5377 (2006.01)
A61P 35/00 (2006.01)
C07B 59/00 (2006.01)
Priority
US 201361750802 P 09.01.2013
PCT application
PCT/US2014/010760 08.01.2014
PCT publication
WO2014/110189 17.07.2014
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Feb 1, 2026

    Change

    Published in Swissreg on 01.02.2026

  2. Feb 1, 2025

    Change

    Published in Swissreg on 01.02.2025

  3. Feb 1, 2024

    Change

    Published in Swissreg on 01.02.2024

  4. Feb 1, 2023

    Change

    Published in Swissreg on 01.02.2023

  5. May 16, 2022

    Address changed

    Representative
    RENTSCH PARTNER AG, Bellerivestrasse 203, Postfach, 8034 Zürich → RENTSCH PARTNER AG, Kirchenweg 8, Postfach, 8034 Zürich

    Published in Swissreg on 16.05.2022

  6. May 1, 2018

    Agent entered

    Representative
    RENTSCH PARTNER AG, Bellerivestrasse 203, Postfach, 8034 Zürich

    Published in Swissreg on 01.05.2018

  7. Apr 11, 2018

    Granted

    Published in Swissreg on 11.04.2018

Parties

Holder

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Inc.

99 Hayden Avenue, Suite 500, Lexington, MA 02421, US

Agent

RENTSCH PARTNER AG

Kirchenweg 8 Postfach, 8034 Zürich

Inventor

SILVERMAN, Robert

Lexington, MA 02421, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.